Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 901 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus Infection Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

NCT00703469
View directory record Official record
Conditions
Hepatitis C
Interventions
MDX1106-02, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • San Francisco, California • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 15, 2026, 1:42 PM EDT
Active, not recruiting Phase 1 Interventional

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

NCT02772003
View directory record Official record
Conditions
Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
Interventions
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 1:42 PM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

NCT00262483
View directory record Official record
Conditions
Hepatitis C
Interventions
VX-950, ribavirin, peginterferon alfa-2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 15, 2026, 1:42 PM EDT
Recruiting Phase 4 Interventional

Implementing Low-Barrier HCV Treatment in a Jail Setting

NCT06953479
View directory record Official record
Conditions
HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR

NCT02669966
View directory record Official record
Conditions
ESRD, Hepatitis C
Interventions
Kidney transplantation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients

NCT03650920
View directory record Official record
Conditions
Liver Failure
Interventions
Liver Transplantation
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient-Centered Care and Asian Americans

NCT02139722
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, Liver Disease
Interventions
Video Doctor, PA + PPN
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

NCT02114151
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Dothan, Alabama • Bakersfield, California • Chula Vista, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 15, 2026, 1:42 PM EDT
Terminated No phase listed Observational

Hepatitis C Lab Testing Comparison Study

NCT06380166
View directory record Official record
Conditions
Hepatitis C
Interventions
Hepatitis C core antigen
Diagnostic Test
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

NCT04137094
View directory record Official record
Conditions
Hiv, Hepatitis C
Interventions
Persuasive Health Communication Intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 15, 2026, 1:42 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

NCT01467479
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 15, 2026, 1:42 PM EDT
Not listed No phase listed Observational

Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

NCT02485262
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir and simeprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01181427
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-267, Placebo, Blood Sample Collection, Cytochrome P450 inhibitor
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Waukegan, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 15, 2026, 1:42 PM EDT
Active, not recruiting Not applicable Interventional

Buprenorphine Integration Research and Community Health

NCT05668780
View directory record Official record
Conditions
Opioid Use Disorder, HIV Infections, Hepatitis C
Interventions
NIATx Coaching
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

NCT02201953
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NCT02113631
View directory record Official record
Conditions
Hepatitis C, Chronic, Cirrhosis
Interventions
Telaprevir, Boceprevir, Peg-IFN, Ribavirin
Drug
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 15, 2026, 1:42 PM EDT
Completed No phase listed Observational Results available

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

NCT01517529
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

NCT02002767
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Velpatasvir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 4 Interventional Results available

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

NCT00107653
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
58
States / cities
Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

NCT00983853
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 4 Interventional

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

NCT00207402
View directory record Official record
Conditions
Hepatitis C
Interventions
rosiglitazone
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 15, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

NCT00565539
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PEGylated recombinant interleukin 29 (PEG-rIL-29)
Drug
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Oct 15, 2026, 1:42 PM EDT